Sharps Tech's Dual Play: Syringes, Solana, and a Show of Confidence

NEW YORK, NY – January 16, 2026 – Sharps Technology, Inc. (NASDAQ: STSS), a company navigating a unique path between medical devices and digital assets, has made another move to bolster market confidence. The firm announced today that its strategic advisor, SOL Markets, has voluntarily entered into a 90-day lock-up agreement, restricting the sale of its advisory warrants and underlying shares. This action comes on the heels of a massive $100 million share buyback program approved late last year, collectively signaling a strong internal belief in the company’s controversial and ambitious strategy.

These financial maneuvers aim to stabilize investor perception of a company that has staked a significant part of its future on the volatile Solana blockchain, even as it continues to operate its foundational business in smart-safety syringes. The lock-up is the latest chapter in a story of a traditional MedTech firm attempting a high-stakes transformation in the world of Web3.

A Powerful Signal of Conviction

The agreement with SOL Markets is a clear vote of confidence. For the next 90 days, the advisor has committed not to “sell, transfer, assign, pledge, hedge, or otherwise dispose of” any of its STSS holdings, which were granted for its advisory services. This move is designed to reinforce alignment and broadcast a shared belief in the company’s roadmap.

“When a long-term partner voluntarily commits to a lock-up, it sends a powerful signal of alignment, conviction, and confidence in the Company’s future,” said Paul Danner, Executive Chairman of STSS, in the official announcement. This sentiment was echoed by Strategic Advisor James Zhang, who added, “We have not sold any shares or warrants thus far, and formalizing this commitment further reflects our confidence in Sharps’ strategy, execution discipline, and near-term catalysts.”

This lock-up does not exist in a vacuum. It follows the Board of Directors' approval on October 2, 2025, for a stock repurchase program of up to $100 million. At the time of the announcement, this figure represented a staggering 55.5% of the company's entire market capitalization. Such a substantial buyback is a classic corporate finance tool used to signal that management believes its stock is deeply undervalued and to enhance shareholder value.

Market response to these signals has been tangible. The stock is currently on a five-day winning streak, closing up over 3% today. Following the October buyback news, retail sentiment on investor platforms like Stocktwits reportedly flipped from 'bearish' to 'bullish,' demonstrating that these confidence-building measures are having at least some of their intended effect on a stock that has experienced extreme volatility.

Beyond Syringes: A Bold Pivot to Blockchain

To understand the need for such strong signals, one must look at Sharps Technology’s dual identity. At its core, the company is an innovative medical device manufacturer. Its product lines, including the FDA-approved SoloGard™ and SecureGard™ safety syringes, are designed to prevent needlestick injuries and ensure single-use compliance. With a 500-million-unit manufacturing facility in Hungary and distribution partnerships with giants like Owens & Minor, Sharps has positioned itself as a key player aiming to resolve supply chain vulnerabilities, particularly those highlighted by recent FDA warnings concerning Chinese-made syringes.

However, in 2025, the company embarked on a radical new course. It adopted a digital asset treasury strategy, raising $411 million through a private placement (PIPE) financing to aggressively accumulate SOL, the native token of the Solana blockchain. By November 2025, Sharps had amassed over 2 million SOL, valued at the time at more than $400 million. This pivot effectively tied a significant portion of the company’s balance sheet and its future to the performance of a single, highly volatile cryptocurrency, a move that introduces substantial risk alongside its potential reward.

Building a Digital Future on Solana's Rails

The company insists its crypto strategy is more than just a passive investment. The stated goal is to leverage its Solana holdings to build a universal framework for digital identity and authentication. To achieve this, Sharps has forged a series of high-profile strategic partnerships with major players in the crypto space, including Crypto.com, Jupiter, and most notably, Coinbase.

In October 2025, Sharps announced it would use Coinbase Prime for institutional-grade custody, liquidity, and over-the-counter (OTC) trading of its SOL treasury. This collaboration deepened just days ago, on January 12, 2026, when Sharps and Coinbase Institutional launched a jointly supported validator on the Solana network. This move marks a critical evolution from being a mere holder of SOL to becoming an active participant in securing and decentralizing the blockchain itself by delegating a portion of its treasury to the validator.

The strategy is already bearing some financial fruit. For the third quarter of 2025, Sharps reported $17.7 million in combined staking revenue and digital-asset gains, demonstrating that its on-chain activities can generate yield beyond simple asset appreciation. It's this active, infrastructure-building approach that the company hopes will differentiate it from other corporations that have merely added digital assets to their balance sheets.

An Unsettled Market and a High-Stakes Bet

Despite the bullish internal signals, the market remains a complex and challenging landscape for STSS. The stock’s 52-week trading range is a testament to its extreme volatility, with a low of $1.65 and a high exceeding $570. Its current market capitalization of approximately $68 million stands in stark contrast to its $100 million buyback authorization and a crypto treasury once valued at over $400 million, suggesting a deep disconnect in valuation.

Ownership is also telling. While institutional ownership remains remarkably low at less than 1%, insiders hold nearly 46% of the company, indicating that those closest to the strategy are heavily invested in its outcome. Recent insider buying activity further supports this, though the picture is complicated by a recent sale from major shareholder Saba Capital Management, L.P., which trimmed its position by nearly 5%.

Adding to the complexity, the company's most recent quarterly earnings report missed analyst consensus estimates, raising questions about the performance of its core operations amidst the focus on the digital asset pivot. Ultimately, Sharps Technology is waging a high-stakes bet on a hybrid future. The recent lock-up and buyback are powerful declarations of intent, but they are aimed at calming a market still grappling with how to value a syringe maker that is simultaneously trying to build the future of digital identity on the blockchain.